Physician profile
Betsy Bailey
NPI 1962474510
$1,805.93
in general payments reported to CMS, 2019-2025
23 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.50 · 2020: $163 · 2021: $379 · 2022: $196 · 2023: $320 · 2024: $525 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $281.45 | 2021-2025 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $232.68 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $197.25 | 2021-2024 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $162.67 | 2021-2023 | |
| Pfizer INC. | $155.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $133.86 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $98.24 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $78.58 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $76.46 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.29 | 2021-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $45.95 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $45.17 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $34.17 | 2024 | Trintellix |
| Alkermes, INC. | $34.03 | 2024-2025 | Aristada, Lybalvi |
| Sun Pharmaceutical Industries INC. | $24.16 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.89 | 2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $18.82 | 2025 | Hetlioz, Fanapt |
| Merck Sharp & Dohme LLC | $18.22 | 2020 | |
| Allergan, INC. | $16.68 | 2020 | |
| Astellas Pharma US INC | $15.97 | 2021 | |
| Neuronetics, INC. | $15.06 | 2023 | Neurostar Tms Therapy System |
| Regeneron Healthcare Solutions, INC. | $14.20 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betsy Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.